TIVC News - Candlesense

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational ...

How does Entolimod’s competitive landscape compare to existing therapies and other pipeline candidates in the immunotherapeutics sector? What is the expected timeline for FDA approval and potential market launch for ARS and advanced cancer indications? How will the IND submissions for Entolimod affect Tivic Health’s upcoming earnings and valuation?

Clinical trials

10 days ago

Read more businesswire

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies throug...

How could this partnership influence Tivic Health's valuation multiples relative to industry peers? Will this news impact Tivic Health's cash burn rate or capital requirements? What are the risks if the discussions with government agencies do not result in tangible agreements?

Partnership

15 days ago

Read more businesswire

Tivic Reports Second Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended...

What are the potential implications of Tivic's strategic transformation for partnership opportunities or M&A activity in the sector? Did management address any regulatory or competitive risks that could affect future revenue streams? How does Tivic's valuation (P/E, EV/EBITDA, price-to-sales) post‑release compare to peers in the immunotherapeutics and bioelectronic sectors?

Earnings

16 days ago

Read more businesswire

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today a...

What technical patterns or volume trends emerged around the release, and could they suggest short‑term trading opportunities? How might the reported results influence analyst coverage, earnings estimates revisions, and target price adjustments? Did the earnings call reveal any unexpected risks or headwinds (e.g., trial setbacks, regulatory challenges, competitive pressures) that could impact the stock?

Earnings

23 days ago

Read more businesswire